Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18596775 | 1.00 | KCNH2 (0.60) | KCNH2TDP1L3MBTL1FAAHCYP19A1 | |
| SCHEMBL27678206 | 1.00 | KCNH2 (0.60) | KCNH2TDP1L3MBTL1FAAHCYP19A1 | |
| SCHEMBL22308558 | 1.00 | KCNH2 (0.60) | KCNH2TDP1L3MBTL1FAAHCYP19A1 | |
| SCHEMBL15573512 | 1.00 | KCNH2 (0.60) | KCNH2TDP1L3MBTL1FAAHCYP19A1 | |
| SCHEMBL22307320 | 1.00 | KCNH2 (0.60) | KCNH2TDP1L3MBTL1FAAHCYP19A1 | |
| SCHEMBL655646 | 0.98 | KCNH2 (0.57) | KCNH2TDP1L3MBTL1FAAHCYP19A1 | |
| SCHEMBL4171814 | 0.92 | KCNH2 (0.48) | KCNH2TDP1L3MBTL1FAAHCYP19A1 | |
| SCHEMBL18222818 | 0.90 | FAAH (0.57) | KCNH2FAAH | |
| SCHEMBL18222821 | 0.90 | FAAH (0.57) | KCNH2FAAH | |
| Piperazine SCHEMBL4836648 | 0.88 | KCNH2 (0.47) | KCNH2TDP1L3MBTL1FAAHCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3443050-A1 | COMPOSITION FOR NANOENCAPSULATION AND NANOCAPSULES COMPRISING A LIQUID-CRYSTALLINE MEDIUM | Merck Patent GmbH (DE) | 2019-02-20 | — | — | EP | disclosed |
| WO-2018189068-A1 | COMPOSITION FOR NANOENCAPSULATION AND NANOCAPSULES COMPRISING A LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018078078-A1 | NANOCAPSULES COMPRISING A LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | WO | disclosed |
| WO-2017178419-A1 | COMPOSITION FOR NANOENCAPSULATION AND NANOCAPSULES COMPRISING A LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017059942-A1 | CHIRAL COMPOUNDS | MERCK PATENT GMBH (DE) | 2017-04-13 | — | — | WO | disclosed |
| US-9409871-B2 | Pyridazinyl derivatives as SMO inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| CN-102143958-B | Pyridazine derivatives as SMO inhibitors | NOVARTIS AG | 2013-12-18 | — | — | CN | disclosed |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-8481542-B2 | Pyridazinyl derivatives as smo inhibitors | NOVARTIS AG (CH) | 2013-07-09 | — | — | US | disclosed |
| EP-2318389-B1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| WO-2002086609-A1 | LIQUID CRYSTAL DEVICE EXHIBITING OPTICAL PROPERTIES WHICH ARE CHANGEABLE AFTER ASSEMBLY | MERCK PATENT GMBH (DE) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002040614-A1 | CHIRAL PHOTOISOMERIZABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002034739-A1 | CHIRAL BINAPHTHOL DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-05-02 | — | — | WO | disclosed |
| WO-2002006196-A1 | CHIRAL COMPOUNDS I | MERCK PATENT GMBH (DE) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002006265-A1 | CHIRAL COMPOUNDS III | MERCK PATENT GMBH (DE) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002006195-A1 | CHIRAL COMPOUNDS II | MERCK PATENT GMBH (DE) | 2002-01-24 | — | — | WO | disclosed |
| EP-0482024-A1 | CHIRAL OR ACHIRAL RING COMPOUNDS. | MERCK PATENT GMBH (DE) | 1992-04-29 | — | — | EP | disclosed |
| EP-0428665-A1 | FLUOROPHENYL PYRIMIDINES. | MERCK PATENT GMBH (DE) | 1991-05-29 | — | — | EP | disclosed |
| EP-0257049-A1 | CHIRAL COMPOUNDS. | MERCK PATENT GMBH (DE) | 1988-03-02 | — | — | EP | disclosed |
| WO-1987005015-A1 | CHIRAL COMPOUNDS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1987-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | SMO, SHH, GLI1 | KCNH2 1554/4885TDP1 4399/4885L3MBTL1 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.